Literature DB >> 32916154

Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease.

Luca Miele1, Maria A Zocco2, Fabrizio Pizzolante3, Nicoletta De Matthaeis3, Maria E Ainora3, Antonio Liguori4, Antonio Gasbarrini2, Antonio Grieco2, Gianludovico Rapaccini2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and represent a common finding in highly prevalent metabolic disorders (i.e. type 2 diabetes, metabolic syndrome, obesity). Non-alcoholic steatohepatitis (NASH) requires liver biopsy for grading and staging the liver damage by the assessment of steatosis, inflammation and fibrosis. In parallel with the development of numerous 'liquid' biomarkers and algorithms that combine anthropometric and laboratory parameters, innovative hepatic imaging techniques have increasingly been developed to attempt to overcome the need for biopsy, both in diagnosis and staging of NAFLD, and in possible use in the follow-up of the disease. In this review, we focused on the different imaging techniques trying to highlight the strengths and disadvantages of different approaches, particularly for ultrasound techniques, in stratifying liver injury and fibrosis in patients with NAFLD / NASH.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fatty liver; Fibroscan; Imaging; Metabolic associated fatty liver disease; NAFLD

Mesh:

Year:  2020        PMID: 32916154     DOI: 10.1016/j.metabol.2020.154355

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  3 in total

1.  A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study.

Authors:  Zhong-Wei Chen; Huan-Ming Xiao; Xinjian Ye; Kun Liu; Rafael S Rios; Kenneth I Zheng; Yi Jin; Giovanni Targher; Christopher D Byrne; Junping Shi; Zhihan Yan; Xiao-Ling Chi; Ming-Hua Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

2.  Hepatic Steatosis Index and the Risk of Type 2 Diabetes Mellitus in China: Insights from a General Population-Based Cohort Study.

Authors:  Xintian Cai; Jing Gao; Shasha Liu; Mengru Wang; Junli Hu; Jing Hong; Qing Zhu; Guzailinuer Tuerxun; Yujie Dang; Nanfang Li
Journal:  Dis Markers       Date:  2022-08-03       Impact factor: 3.464

Review 3.  Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use.

Authors:  Thirza van Deuren; Ellen E Blaak; Emanuel E Canfora
Journal:  Obes Rev       Date:  2022-07-20       Impact factor: 10.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.